| Michael W. Weiner | |
|---|---|
| Photo placeholder | |
| Affiliations | University of California, San Francisco |
| Country | USA |
| H-index | 200 |
| ORCID | 0000-0002-2777-8648 |
| Research Focus | Alzheimer's Disease, Neuroimaging, Biomarkers |
| Mechanisms | MRI, PET imaging, Biomarkers, Prevention trials |
Michael W. Weiner is a pioneering researcher in the use of neuroimaging and biomarkers for Alzheimer's disease diagnosis and tracking. As director of the Alzheimer's Disease Neuro (ADNI)imaging Initiative and leader of numerous large-scale multi-site studies, Dr. Weiner has transformed how Alzheimer's disease is diagnosed and monitored in clinical practice and research.
Dr. Weiner completed his medical training and radiology residency at UCSF, where he also pursued research training in nuclear medicine and neuroimaging. He has been a professor at UCSF for over three decades and has established one of the premier neuroimaging research programs in the world.
Dr. Weiner founded and leads ADNI, one of the most influential research programs in Alzheimer's disease:
His neuroimaging research has focused on:
He has led efforts to validate biomarkers for Alzheimer's disease:
Dr. Weiner has been central to Alzheimer's prevention initiatives:
Dr. Weiner has authored over 600 peer-reviewed publications and is one of the most cited researchers in the field of neuroimaging and Alzheimer's disease.
Dr. Weiner's contributions have transformed Alzheimer's research globally:
His work continues to drive advances in understanding and treating these devastating diseases, with ongoing studies exploring novel therapeutic approaches and early intervention strategies.
Dr. Weiner leads a clinical imaging program that provides state-of-the-art neuroimaging services for patients with memory disorders. The program integrates cutting-edge MRI and PET imaging techniques with clinical assessment to provide definitive diagnoses and guide treatment decisions.
This clinical program serves as a bridge between research and patient care, ensuring that advances in neuroimaging technology translate into improved diagnostic accuracy and patient outcomes.